0001209191-20-034882.txt : 20200605
0001209191-20-034882.hdr.sgml : 20200605
20200605212927
ACCESSION NUMBER: 0001209191-20-034882
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200604
FILED AS OF DATE: 20200605
DATE AS OF CHANGE: 20200605
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boissel Stephane
CENTRAL INDEX KEY: 0001755198
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 20947934
MAIL ADDRESS:
STREET 1: C/O SANGAMO THERAPEUTICS, INC.
STREET 2: POINT RICHMOND TECH CTR, 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 501 CANAL BLVD
STREET 2: POINT RICHMOND TECH CNTR.
CITY: RICHMOND
STATE: CA
ZIP: 94804
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-06-04
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001755198
Boissel Stephane
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD
BRISBANE
CA
94005
0
1
0
0
EVP, Corp. Strategy
Common Stock
2020-06-04
4
M
0
14907
A
85023
D
Common Stock
2020-06-04
4
D
0
14907
11.23
D
70116
D
Free Shares Put Option (right to sell to Issuer)
2.0925
2020-06-04
4
M
0
1
0.00
D
2020-05-10
2020-07-10
Common Stock
14907
2
D
In connection with the acquisition by the Issuer of Sangamo Therapeutics France S.A.S. (formerly TxCell S.A.) ("Sangamo France"), the Reporting Person was granted the right to sell to the Issuer up to 238,100 "free shares" of Sangamo France (the "Subject Free Shares") for cash in four separate tranches beginning July 4, 2019 (the "Free Shares Put Options"). The exercise price per Subject Free Share to be paid by the Issuer upon the Reporting Person's exercise of its Free Shares Put Options is equal to the product of 2.58 euros times the quotient of the 20-day volume weighted average price of the Issuer's common stock preceding the date the Reporting Person notifies the Issuer of its exercise of its Free Shares Put Options (as converted to euros) divided by 12.8329. On June 4, 2020, the Reporting Person exercised his Free Shares Put Option with respect to the second tranche of Subject Free Shares (SEE FOOTNOTE (2) FOR CONTINUATION OF EXPLANATION)
(or 80,000 Subject Free Shares) (the "Second Tranche Shares") in exchange for a cash payment of 148,800 euros, or approximately 1.86 euros per Second Tranche Share. The Reporting Person's exercise of his Free Shares Put Option with respect to the Second Tranche Shares for cash is deemed, for reporting purposes, to involve the conversion of the Second Tranche Shares into shares of the Issuer's common stock and the simultaneous disposition of such common stock to the Issuer for cash. The June 4, 2020 euro to U.S. dollar exchange rate of 1.1250 was used for purposes of reporting the exercise price and the number of shares of the Issuer's common stock that was deemed to have been acquired and simultaneously disposed of by the Reporting Person upon exercise.
/s/ Matthew Colvin, Attorney-in-Fact for Stephane Boissel
2020-06-05